Pharma Update

Roche PHESGO® Phesgo: Rapid conversion in early launch countries Significantly reducing healthcare costs and resource use Treatment option Phesgo reduces administration time & costs Administration and observation schedule* Strong global launch Global Phesgo conversion rate at 35%* Π 0.5 1.5 hours HIV PIV 5 - 8 min 15-30 min Phesgo • · . 2-6h 1h <-1h- Administration time Ranges driven by differences in loading and maintenance dose Total time 40% ~2.5-7.5 hours 30% 20% 10% ~20-38 min 0% Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 20 21 21 21 21 22 22 22 22 23 23 85% of patients preferred Phesgo for subcutaneous administration over the intravenous formulation of Perjeta and Herceptin Phesgo conversion rate at 35% in early launch countries; conversion in key markets: UK 92%, France, 59%, US: 19%, Germany 16% Phesgo expanding eBC market share • Pivotal Phesgo on-body-injector (OBI) development ongoing Source: O'Shaughnessy J, et al. ESMO 2020 (Abstract 165MO); H-Herceptin; P=Perjeta; IV-Intravenous; *Ranges driven by differences in loading and maintenance dose; *Perjeta/Phesgo conversion rate is based on volumes (vials) and includes all launch countries after the 2nd quarter after the launch (38 countries); Phesgo in collaboration with Halozyme 56 56

View entire presentation